Hyperglycemia and chronic liver diseases on risk of hepatocellular carcinoma in Chinese patients with type 2 diabetes––National cohort of Taiwan Diabetes Study
Chia-Ing Li
School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan
Department of Medical Research, China Medical University Hospital, Taichung, Taiwan
C.-I.L. and H.-J.C. Authors share co-senior authorship.
Search for more papers by this authorHsuan-Ju Chen
Management Office for Health Data, China Medical University Hospital, Taichung, Taiwan
School of Public Health, College of Public Health, China Medical University, Taichung, Taiwan
C.-I.L. and H.-J.C. Authors share co-senior authorship.
Search for more papers by this authorHsueh-Chou Lai
School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan
Division of Hepatogastroenterology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan
Search for more papers by this authorChiu-Shong Liu
School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan
Department of Medical Research, China Medical University Hospital, Taichung, Taiwan
Department of Family Medicine, China Medical University Hospital, Taichung, Taiwan
Search for more papers by this authorWen-Yuan Lin
School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan
Department of Family Medicine, China Medical University Hospital, Taichung, Taiwan
Search for more papers by this authorCorresponding Author
Tsai-Chung Li
Graduate Institute of Biostatistics, College of Management, China Medical University, Taichung, Taiwan
Department of Healthcare Administration, College of Health Science, Asia University, Taichung, Taiwan
Correspondence to: Cheng-Chieh Lin and Tsai-Chung Li, China Medical University, 91 Hsueh-Shih Road, Taichung 40421, Taiwan, Tel.: 886-4-2205-2121, ext. 7629, Fax: 886-4-2207-8539, E-mail: [email protected]Search for more papers by this authorCorresponding Author
Cheng-Chieh Lin
School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan
Department of Medical Research, China Medical University Hospital, Taichung, Taiwan
Department of Family Medicine, China Medical University Hospital, Taichung, Taiwan
Correspondence to: Cheng-Chieh Lin and Tsai-Chung Li, China Medical University, 91 Hsueh-Shih Road, Taichung 40421, Taiwan, Tel.: 886-4-2205-2121, ext. 7629, Fax: 886-4-2207-8539, E-mail: [email protected]Search for more papers by this authorChia-Ing Li
School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan
Department of Medical Research, China Medical University Hospital, Taichung, Taiwan
C.-I.L. and H.-J.C. Authors share co-senior authorship.
Search for more papers by this authorHsuan-Ju Chen
Management Office for Health Data, China Medical University Hospital, Taichung, Taiwan
School of Public Health, College of Public Health, China Medical University, Taichung, Taiwan
C.-I.L. and H.-J.C. Authors share co-senior authorship.
Search for more papers by this authorHsueh-Chou Lai
School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan
Division of Hepatogastroenterology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan
Search for more papers by this authorChiu-Shong Liu
School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan
Department of Medical Research, China Medical University Hospital, Taichung, Taiwan
Department of Family Medicine, China Medical University Hospital, Taichung, Taiwan
Search for more papers by this authorWen-Yuan Lin
School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan
Department of Family Medicine, China Medical University Hospital, Taichung, Taiwan
Search for more papers by this authorCorresponding Author
Tsai-Chung Li
Graduate Institute of Biostatistics, College of Management, China Medical University, Taichung, Taiwan
Department of Healthcare Administration, College of Health Science, Asia University, Taichung, Taiwan
Correspondence to: Cheng-Chieh Lin and Tsai-Chung Li, China Medical University, 91 Hsueh-Shih Road, Taichung 40421, Taiwan, Tel.: 886-4-2205-2121, ext. 7629, Fax: 886-4-2207-8539, E-mail: [email protected]Search for more papers by this authorCorresponding Author
Cheng-Chieh Lin
School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan
Department of Medical Research, China Medical University Hospital, Taichung, Taiwan
Department of Family Medicine, China Medical University Hospital, Taichung, Taiwan
Correspondence to: Cheng-Chieh Lin and Tsai-Chung Li, China Medical University, 91 Hsueh-Shih Road, Taichung 40421, Taiwan, Tel.: 886-4-2205-2121, ext. 7629, Fax: 886-4-2207-8539, E-mail: [email protected]Search for more papers by this authorConflict of interest statement: None declared.
Abstract
This study examined whether glycated hemoglobin A1C (HbA1C) and chronic liver diseases are associated with hepatocellular carcinoma (HCC) risk in Type 2 diabetic patients. A retrospective cohort study consisting of 51,705 patients with Type 2 diabetes aged 30 and over enrolled in the National Diabetes Care Management Program before 2004 was used in Cox proportional hazards models. HbA1C was independently associated with HCC incidence, and multivariate-adjusted hazard ratio (HR) of HCC was 1.20 (95% confidence interval, CI: 1.02–1.41) for patients with a level of HbA1c ≥ 9% compared with patients with a level of HbA1c <7% after multivariate adjustment. We observed a significant linear trend in HCC incidence with increasing HbA1c (p for trend = 0.02, HR = 1.07, 95% CI = 1.01–1.12 for every 1% increment in HbA1c). We observed significant HRs of HCC for patients with a level of HbA1c ≥ 9% with alcoholic liver damage, liver cirrhosis, HBV, HCV and any one of chronic liver diseases compared with patients with a level of HbA1c <9% and no counterpart comorbidity in the entire sample (HR = 8.63, 95% CI = 1.41–52.68; HR = 5.02, 95% CI = 3.10–8.12; HR = 2.53, 95% CI = 1.10–5.85; HR = 1.79, 95% CI = 1.01–3.17; and HR = 3.59, 95% CI = 2.56–5.02, respectively). Our results suggest significant joint associations of HbA1c ≥ 9% and chronic liver diseases. Lifestyle or treatment interventions such as maintaining a satisfactory glycemic control and chronic liver diseases may reduce the burden of HCC.
Abstract
What's new?
This is the first study to examine whether glucose control as measured with HbA1c level and chronic liver diseases are associated with hepatocellular carcinoma (HCC) in Chinese type-2 diabetic patients. A positive association was found between HbA1c level and HCC risk, with a level of HbA1c ≥ 9% being a predictor of HCC risk. Furthermore, the level of HbA1c ≥ 9% and chronic liver diseases were significantly jointly associated with HCC risk. HCC incidence is rapidly increasing worldwide, and lifestyle or treatment interventions to maintain a satisfactory control over glycemia and chronic liver diseases may reduce the burden of HCC.
References
- 1International Agency for Research on Cancer. GLOBOCAN 2008. Available at: http://globocan.iarc.fr/. Accessed August 1, 2014.
- 2 Registry TC. Age-standardized incidence of liver and intrahepatic bile duct cancer of the long-time trend. Available at: http://cph.ntu.edu.tw/uploadimages/Year_Digestive.xls. Accessed August 1, 2014.
- 3International Diabetes Federation. About diabetes-risk factor. Available at: http://www.idf.org/about-diabetes/risk-factors. Accessed August 1, 2014.
- 4 El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004; 126: 460–8.
- 5 Fujino Y, Mizoue T, Tokui N, et al. Prospective study of diabetes mellitus and liver cancer in Japan. Diab Metab Res Rev 2001; 17: 374–9.
- 6
Keitaro Tanaka,
Ichiro Tsuji,
Akiko Tamakoshi, et al. Diabetes mellitus and liver cancer risk: an evaluation based on a systematic review of epidemiologic evidence among the japanese population. Jpn J Clin Oncol 2014. doi:10.1093/jjco/hyu108.
10.1093/jjco/hyu108 Google Scholar
- 7 Printz C. Diabetes associated with increased risk of liver cancer. Cancer 2014; 120: 1288.
- 8 Chiang CH, Lee LT, Hung SH, et al. Opposite association between diabetes, dyslipidemia, and hepatocellular carcinoma mortality in the middle-aged and elderly. Hepatology 2014; 59: 2207–15.
- 9World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR). Food, nutrition and the prevention of cancer: a global perspective. Washington, DC: WCRF/AICR, 1997.
- 10
Grimberg A,
Cohen P. Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis. J Cell Physiol 2000; 183: 1–9.
10.1002/(SICI)1097-4652(200004)183:1<1::AID-JCP1>3.0.CO;2-J CAS PubMed Web of Science® Google Scholar
- 11 Chan JM, Stampfer MJ, Giovannucci E, et al. Plasma insulin-like growth factor-1 and prostate cancer risk: a prospective study. Science 1998; 279: 563–6.
- 12 Bohlke K, Cramer DW, Trichopoulos D, et al. Insulin-like growth factor-1 in relation to premenopausal ductal carcinoma in situ of the breast. Epidemiology 1998; 9: 570–3.
- 13 Cohen P, Clemmons DR, Rosenfeld RG. Does the GH-IGF axis play a role in cancer pathogenesis? Growth Horm IGF Res 2000; 10: 297–305.
- 14 Lee DF, Kuo HP, Chen CT, et al. IKKbeta suppression of TSC1 function links the mTOR pathway with insulin resistance. Int J Mol Med 2008; 22: 633–8.
- 15 Greten FR, Eckmann L, Greten TF, et al. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004; 118: 285–96.
- 16 Hu MC, Lee DF, Xia W, et al. IKappa B kinase promotes tumorigenesis through inhibition of forkhead FOXO3a. Cell 2004; 117: 225–37.
- 17 Lee DF, Kuo HP, Chen CT, et al. IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway. Cell 2007; 130: 440–55.
- 18 Rahbar S. The discovery of glycated hemoglobin: a major event in the study of nonenzymatic chemistry in biological systems. Ann N Y Acad Sci 2005; 1043: 9–19.
- 19 UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837–53.
- 20 The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977–86.
- 21 Shichiri M, Kishikawa H, Ohkubo Y, et al. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diab Care 2000; 23 (Suppl 2): B21–B29.
- 22 Selvin E, Marinopoulos S, Berkenblit G, et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 2004; 141: 421–31.
- 23 Adler AI, Stevens RJ, Neil A, et al. UKPDS 59: hyperglycemia and other potentially modifiable risk factors for peripheral vascular disease in type 2 diabetes. Diab Care 2002; 25: 894–9.
- 24 Kothari V, Stevens RJ, Adler AI, et al. UKPDS 60: risk of stroke in type 2 diabetes estimated by the UK Prospective Diabetes Study risk engine. Stroke 2002; 33: 1776–81.
- 25 Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405–12.
- 26 Turner RC, Millns H, Neil HA, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 1998; 316: 823–8.
- 27 Adler AI, Neil HA, Manley SE, et al. Hyperglycemia and hyperinsulinemia at diagnosis of diabetes and their association with subsequent cardiovascular disease in the United Kingdom prospective diabetes study (UKPDS 47). Am Heart J 1999; 138: S353–S359.
- 28 Stevens RJ, Coleman RL, Adler AI, et al. Risk factors formyocardial infarction case fatality and stroke case fatality in type 2 diabetes: UKPDS 66. Diab Care 2004; 27: 201–7.
- 29 Joshu CE, Prizment AE, Dluzniewski PJ, et al. Glycated hemoglobin and cancer incidence and mortality in the Atherosclerosis in Communities (ARIC) Study, 1990–2006. Int J Cancer 2012; 131: 1667–77.
- 30 Silbernagel G, Grammer TB, Winkelmann BR, et al. Glycated hemoglobin predicts all-cause, cardiovascular, and cancer mortality in people without a history of diabetes undergoing coronary angiography. Diab care 2011; 34: 1355–61.
- 31 Saydah S, Tao M, Imperatore G, et al. GHb level and subsequent mortality among adults in the U.S. Diab care 2009; 32: 1440–6.
- 32 Miao Jonasson J, Cederholm J, Eliasson B, et al. HbA1C and cancer risk in patients with type 2 diabetes-a nationwide population-based prospective cohort study in Sweden. PloS one 2012; 7: e38784.
- 33 Sluik D, Boeing H, Montonen J, et al. HbA1c measured in stored erythrocytes is positively linearly associated with mortality in individuals with diabetes mellitus. PloS one 2012; 7: e38877.
- 34 Dabrowski M. Glycated hemoglobin, diabetes treatment and cancer risk in type 2 diabetes. A case-control study. Ann Agric Environ Med 2013; 20: 116–21.
- 35 Yang X, Wang Y, Luk AO, et al. Enhancers and attenuators of risk associations of chronic hepatitis B virus infection with hepatocellular carcinoma in type 2 diabetes. Endocr Relat Cancer 2013; 20: 161–71.
- 36 Donadon V, Balbi M, Valent F, et al. Glycated hemoglobin and antidiabetic strategies as risk factors for hepatocellular carcinoma. World J Gastroenterol 2010; 16: 3025–32.
- 37 de Beer JC, Liebenberg L. Does cancer risk increase with HbA1c, independent of diabetes? BJC 2014; 110: 2361–8.
- 38 Yang X, Ko GT, So WY, et al. Associations of hyperglycemia and insulin usage with the risk of cancer in type 2 diabetes: the Hong Kong diabetes registry. Diabetes 2010; 59: 1254–60.
- 39Department of Health, Executive Yuan. The National Health Insurance Statistics, 2010. Available at: http://www.nhi.gov.tw/English/webdata/webdata.aspx?menu=11&menu_id=296&WD_ID=296&webdata_id=4010. Accessed August 1, 2014.
- 40 Cheng CL, Kao YH, Lin SJ, et al. Validation of the National Health Insurance Research Database with ischemic stroke cases in Taiwan. Pharmacoepidemiol Drug Saf 2011; 20: 236–42.
- 41 Kang JH, Chen YH, Lin HC. Comorbidity profiles among patients with ankylosing spondylitis: a nationwide population-based study. Ann Rheum Dis 2010; 69: 1165–8.
- 42 Christman AL, Lazo M, Clark JM, et al. Low glycated hemoglobin and liver disease in the U.S. population. Diab care 2011; 34: 2548–50.
- 43 Ma H, Xu C, Xu L, et al. Independent association of HbA1c and nonalcoholic fatty liver disease in an elderly Chinese population. BMC Gastroenterol 2013; 13: 3.
- 44 Lai SW, Chen PC, Liao KF, et al. Risk of hepatocellular carcinoma in diabetic patients and risk reduction associated with anti-diabetic therapy: a population-based cohort study. Am J Gastroenterol 2012; 107: 46–52.
- 45 Parekh S, Anania FA. Abnormal lipid and glucose metabolism in obesity: implications for nonalcoholic fatty liver disease. Gastroenterology 2007; 132: 2191–207.
- 46 Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006; 43 (2 Suppl 1): S99–S112.
- 47 Yang X, So WY, Ma RC, et al. Diabetes and cancer: the mechanistic implications of epidemiological analyses from the Hong Kong Diabetes Registry. Diab Metab Res Rev 2012; 28: 379–387.
- 48 White DL, Kanwal F, El-Serag HB. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin Gastroenterol Hepatol 2012; 10: 1342–59.
Citing Literature
